Fig. 3.

Disease activity as measured by DAS28-4(ESR) in patients with RA receiving bDMARDs

(A) Estimated marginal mean DAS28-4(ESR) score and mean changes from baseline in DAS28-4(ESR) score in patients receiving bDMARDs over 24 months, and (B) proportion of bDMARD-treated patients achieving DAS28-4(ESR)-defined remission, LDA, MDA and HDA at Month 12 according to disease activity at Month 6. ^abDMARD monotherapy: n = 396; bDMARDs + MTX: n = 1460; bDMARDs + other csDMARDs: n = 208. Δ: change from baseline; bDMARD: biologic DMARD; csDMARDs: conventional synthetic DMARDs; DAS28-4(ESR): DAS in 28 joints, ESR; HDA: high disease activity; LDA: low disease activity; MDA: moderate disease activity.